Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • PZWL - dla zawodowców
  • Obniżka
Clinical Dilemmas in Viral Liver Disease

Clinical Dilemmas in Viral Liver Disease

9781119533399
409,50 zł
368,55 zł Zniżka 40,95 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 368,55 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD lub Pocztę Polską. Kliknij po więcej szczegółów

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni. Kliknij po więcej szczegółów

Opis
The only evidence-based book to approach viral liver disease by focusing exclusively on the clinical dilemmas encountered by hepatologists and their medical teams Although viral hepatitis is a growing public health risk around the world, the World Health Organization (WHO) views the elimination of hepatitis infection over the next several as an achievable goal. Effective pharmaceutical therapies are now available, yet medical teams caring for patients with viral hepatitis are challenged when looking for answers to specific questions in the current medical literature. The second edition of Clinical Dilemmas in Viral Liver Disease provides evidence-based guidance for medical teams involved in diagnosing, treating, and managing patients with viral liver disease. This fully updated book explores developments in new treatments and new diagnostic approaches that are contributing to WHO goals of viral elimination. Brief, easily referenced chapters examine clearly defined topics, addressing the clinical questions and difficulties encountered by medical teams in day-to-day practice. Contributions by an international team of investigators and clinicians address clinical questions and issues which are seldom found in standard textbooks and online repositories. Offering practical guidance on the specific challenges and dilemmas of treating viral liver disease, this unique volume::  Provides practical, evidence-based guidance on topical and controversial issues Addresses understudied questions that arise in day-to-day clinical practice Discusses the challenges surrounding global elimination programs Presents focused approach that is supported by current literature and expert opinion The second edition of Clinical Dilemmas in Viral Liver Disease is required reading for practicing and trainee hepatologists, gastroenterologists, transplant surgeons, virologists, and other practitioners involved in caring for patients with liver disease.
Szczegóły produktu
John Wiley and Sons
82549
9781119533399
9781119533399

Opis

Rok wydania
2020
Numer wydania
1
Oprawa
miękka foliowana
Liczba stron
272
Wymiary (mm)
201.00 x 230.00
Waga (g)
508
  • List of Contributors vii Preface xi Part I:: Investigating the Liver 1 Noninvasive markers of fibrosis:: how reliable are they? 3 Laurent Castera 2 Liver biopsy in chronic viral hepatitis:: is there still life left in it? 9 Jaspreet Suri and Michael P. Curry 3 Screening for hepatocellular carcinoma in viral liver disease:: any new biomarkers on the horizon? 15 Saroja Bangaru, Jorge A. Marrero, and Amit G. Singal 4 Realistic estimates of hepatitis C virus and hepatitis B virus disease burden 19 Homie Razavi Part II:: Today’s Therapies Section 1:: HCV 5 Acute hepatitis C:: treat immediately or give a chance to spontaneously clear? 29 David E. Kaplan 6 Is ribavirin alive or dead in the current era of HCV therapy? 35 Vijay Prabhakar and Paul Y. Kwo 7 Hepatitis C virus genotype and viral testing, and on‐treatment monitoring:: necessary or overkill? 41 Sirina Ekpanyapong and K. Rajender Reddy 8 Treatment of hepatitis C virus in renal disease:: can we use all the drugs without additional monitoring? 48 Stanislas Pol 9 Does directly acting antiviral therapy improve quality of life? 54 Daniel M. Forton 10 Morbid obesity and hepatitis C:: treat as normal or are there additional issues to consider? 59 María Fernanda Guerra, Javier Ampuero, and Manuel Romero‐Gómez 11 Generic direct‐acting antiviral agents:: do they work well? 66 Omar Salim Al Siyabi and Seng‐Gee Lim 12 Impact and management of patients with multiple hepatitis C virus genotypes 74 Peter Ferenci 13 Hepatitis C virus and injecting drug use:: what are the challenges? 78 Olav Dalgard 14 Hepatitis B virus reactivation while on hepatitis C virus direct‐acting antiviral therapy:: is that a real concern and when is it a concern? 82 Marina Serper 15 Drug–drug interactions with direct‐acting antivirals:: when do we need to care? 86 Fiona Marra and David Back 16 Treatment of hepatitis C in children 94 Maureen M. Jonas 17 While direct‐acting antivirals are effective, are there any unique safety considerations? 97 Olivia Pietri, Félix Trottier‐Tellier, and Marc Bourlière 18 Harm reduction strategies to prevent new infections and reinfections among people who inject drugs:: how effective are they? 106 Jason Grebely and Marianne Martinello 19 Hepatitis C virus therapy in advanced liver disease:: treat or transplant and treat? 112 Chalermrat Bunchorntavakul and K. Rajender Reddy 20 Hepatocellular carcinoma and hepatitis C virus:: which should be treated first? 117 Mario U. Mondelli, Andrea Lombardi, and Massimo Colombo 21 Should we incentivize patients to take hepatitis C virus therapy? 122 Ed Gane 22 Treating prisoners with hepatitis C:: should we do it and how? 125 Seth Francis‐Graham and William Rosenberg 23 Use of hepatitis C virus‐positive organs for uninfected recipients in the era of effective and safe direct‐acting antivirals:: pros and cons 132 Sirina Ekpanyapong and K. Rajender Reddy 24 Is real‐life hepatitis C virus therapy as effective as in clinical trials? 138 Jessica Su and Joseph K. Lim Section 2:: HBV, HDV, and HEV 25 Management of acute hepatitis B infection:: when should we offer antiviral therapy? 145 Emma Hathorn and David J. Mutimer 26 Rethinking the inactive carrier state:: management of patients with low‐replicative HBeAg‐negative chronic hepatitis B and normal liver enzymes 150 María Buti, Mar Riveiro‐Barciela, and Rafael Esteban 27 Hepatitis B e antigen‐positive chronic hepatitis B infection with minimal changes on liver biopsy:: what to do next 156 Apostolos Koffas and Patrick T. Kennedy 28 The management of hepatitis B virus in pregnancy 160 Henry L.Y. Chan 29 Treatment of hepatitis B in children 164 Maureen M. Jonas 30 Hepatitis B vaccine failures:: how do we handle them? 169 Daniel Shouval 31 The stopping rules in hepatitis B virus therapy:: can we provide any guidance? 175 Florian van Bömmel and Thomas Berg 32 Hepatitis C and hepatitis B coinfection 182 Chun‐Jen Liu and Jia‐Horng Kao 33 Chronic hepatitis E virus infection:: is it reality or hype and where does it matter? 189 Nassim Kamar and Jacques Izopet 34 Hepatitis E virus vaccines:: have they arrived – when, where and for whom? 193 Amit Goel and Rakesh Aggarwal Part III:: Clinical Set‐up and the Future 35 Do we need expert hepatitis C virus treaters or are amateur treaters good enough? 203 Shyamasundaran Kottilil and Poonam Mathur 36 Hepatitis C vaccines:: how close are we to the promised land? 208 Timothy Donnison, Senthil Chinnakannan, Paola Cicconi, and Eleanor Barnes 37 Elimination of hepatitis C virus in high‐prevalence, low‐income countries:: is it feasible? 216 Mahmoud Abdo and Hadeel Gamal Eldeen 38 Hepatitis B virus diagnostics:: anything new? 220 Dina Ginzberg, Robert J. Wong, and Robert G. Gish Part IV:: Ongoing Controversies 39 Is hepatocellular carcinoma risk impacted favorably or unfavorably by hepatitis C virus therapy with direct‐acting antivirals? 233 Giuseppe Cabibbo, Calogero Cammà, and Antonio Craxì 40 Global elimination of hepatitis C virus by 2030:: the optimistic view 238 Gregory J. Dore and Marianne Martinello 41 Global elimination of hepatitis C virus by 2030:: the pessimistic view 244 Thomas G. Cotter and Michael Charlton Index 250
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów